0
Abstract: Case Reports |

Drotrecogin Alfa Use for Severe Sepsis Following Coronary Artery Bypass Graft Surgery FREE TO VIEW

Shahid Yakoob, MBBS; Bryan Veynovich, DO, FCCP; Brian Carlin, MD, FCCP; Khalid Malik, MD, FCCP; Lawrence Crist, DO; Deepak Singh, MD
Author and Funding Information

Allegheny General Hospital, Pittsburgh, PA


Chest


Chest. 2003;124(4_MeetingAbstracts):302S. doi:10.1378/chest.124.4_MeetingAbstracts.302S
Text Size: A A A
Published online

INTRODUCTION:  Drotrecogin alfa is a newer therapy available for the treatment of severe sepsis. Its use is not well studied in patients following coronary artery bypass graft surgery (CABG). We present a patient who developed sepsis following CABG in which treatment with drotrecogin alfa resulted in significant improvement.

CASE PRESENTATION:  A 78 year-old male presented with an acute myocardial infarction and left ventricular dysfunction (ejection fraction 10%) treated with heparin, aspirin and clopidogrel. He developed hypotension during a cardiac catheterization and required intra-aortic balloon pump support. He underwent emergent CABG. Following surgery his cardiac function improved (EF 30%). He required mechanical ventilatory assistance and four days later developed increased tracheal secretions which decreased following antibiotic therapy. Six days later he developed fever (39.1c), hypotension, leukocytosis, renal failure, and a left upper lobe infiltrate. Intravenous fluids, dobutamine, norepinephrine, phenylephrine and epinephrine were needed to maintain a mean arterial pressure of 60 torr. A transesophageal echo showed biventricular dysfunction (EF 10%). Sepsis due to pneumonia was diagnosed and drotrecogin alfa was started. His hemodynamics improved significantly and he was able to be weaned from the pressor support within five hours. No significant bleeding occurred thereafter. He was transferred from the intensive care unit but he required ventilatory and dialysis support. A decision was made by the family not to maintain ongoing dialytic support. He died thirty days later.DISCUSSION: This case represents the use of drotrecogin alfa in a patient with severe sepsis developing soon after CABG. Drotrecogin alfa is useful for patients with severe sepsis but its use for patients treated with anticoagulant and antiplatelet agents and/or CABG has not been studied. Our patient with cardiogenic shock was treated with aspirin, clopidogrel and CABG. Sepsis, unresponsive to pressor agents, was treated with drotrecogin alfa with dramatic improvement in hemodynamics within several hours and without significant bleeding.

CONCLUSION:  Drotrecogin alfa should be considered for the treatment of severe sepsis in a patient following CABG.

DISCLOSURE:  S. Yakoob, None.

Tuesday, October 28, 2003

4:15 PM - 5:45 PM

References

Gordon R. Bernard, Efficacy and safety of Recombinant human activated Protein C for severe sepsis.New England Journal of Medicine344(10)2001699–709
 
Gordon R. Bernard, Safety and close relationship of recombinant human activated protein C for coagulopathy in severe sepsis.Critical Care Medicine(29)20012051–2059
 

Figures

Tables

References

Gordon R. Bernard, Efficacy and safety of Recombinant human activated Protein C for severe sepsis.New England Journal of Medicine344(10)2001699–709
 
Gordon R. Bernard, Safety and close relationship of recombinant human activated protein C for coagulopathy in severe sepsis.Critical Care Medicine(29)20012051–2059
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543